Investor Home

Investor Home

Webcast ImageWebcast
Nabriva Therapeutics LEAP 1 Phase 3 Trial Topline Results Conference Call (Replay)
09/18/17 at 8:30 a.m. ET
Nabriva Therapeutics LEAP 1 Phase 3 Trial Topline Results Conference Call
Monday, September 18, 2017 8:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast
Nabriva Therapeutics at 2017 Cantor Fitzgerald Global Healthcare Conference (Live)
09/25/17 at 2:25 p.m. ET
Nabriva Therapeutics at 2017 Cantor Fitzgerald Global Healthcare Conference
Monday, September 25, 2017 2:25 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Corporate Profile

Nabriva is developing its lead product candidate, lefamulin, to be the first pleuromutilin antibiotic available for systemic administration in humans. We are developing both intravenous (IV) and oral formulations of lefamulin for the treatment of community-acquired bacterial pneumonia (CABP) and intend to develop lefamulin for additional indications other than pneumonia.

Lefamulin

Nabriva’s lead pleuromutilin product candidate, lefamulin, is being studied for the treatment of moderate to severe CABP. We have completed the LEAP 1 Phase 3 trial ... More >>

Recent Newsmore >
09/20/17
Nabriva Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference
DUBLIN, Ireland and KING OF PRUSSIA, Pa., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the research and development of new medicines to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that Chief Executive Officer Colin Broom, M.D., will provide a company overview, including the previously released lefamulin evaluation against pneumonia (LEAP 1) Phase 3 trial topline results, a... 
09/19/17
Nabriva Therapeutics Announces Pricing of Public Offering of Ordinary Shares of Approximately $80 Million
DUBLIN, Ireland and KING OF PRUSSIA, Pa., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV) today announced the pricing of its underwritten public offering of 9,411,765 ordinary shares at a public offering price of $8.50 per share. In addition, Nabriva Therapeutics has granted the underwriters an option for a period of 30 days to purchase up to an additional 1,411,764 ordinary shares at the public offering price, less the underwriting discounts and commissions. All of t... 
09/18/17
Nabriva Therapeutics Announces Proposed Public Offering of Ordinary Shares
DUBLIN, Ireland and KING OF PRUSSIA, Pa., Sept. 18, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV) today announced that it has commenced an underwritten public offering of $80.0 million of ordinary shares. In addition, Nabriva Therapeutics expects to grant the underwriters an option for a period of 30 days to purchase up to an additional $12.0 million of ordinary shares at the public offering price, less the underwriting discounts and commissions. All of the ordinary shares in... 
Upcoming Eventsmore >
DateTitleRemind
Me
Prior to
Event
09/25/17 2:25 p.m. ET
Nabriva Therapeutics at 2017 Cantor Fitzgerald Global Healthcare Conference
days
Enter your e-mail address 
Data provided by Nasdaq. Minimum 15 minutes delayed.